Page 147 - 2019_06-Haematologica-web

Higher TBI dose improves NMA conditioning HCT for MDS or MPN
high rate of disease progression or relapse. We showed that an incremental increase in TBI resulted in a lower risk of dis- ease progression/relapse among patients with MDS, MPN, and CMML. However, the escalation of the TBI dose to 450 cGy was associated with increased NRM, offsetting the ben- efit achieved from decreased disease recurrence. Future stud- ies will, therefore, employ targeted radioimmunotherapy in order to reduce relapse/progression without added toxicity and without increasing NRM.
Acknowledgments
We thank the patients who have participated in this trial along with the clinical staff and research staff who assisted in the con-
duct of the trial. We also thank Helen Crawford for help with manuscript preparation and submission.
Funding
Support for this study was provided from grants CA078902 from National Cancer Institute and grant HL36444 from the National Heart, Lung and Blood Institute, National Institutes of Health. This work was also in part supported by the NIH/NCI Cancer Center Support Grant P30 CA015704. The content is solely the responsibility of the authors and does not necessarily rep- resent the official views of the National Cancer Institute or the National Institutes of Health nor their subsidiary Institutes and Center.
References
1. Scott B, Deeg HJ. Hemopoietic cell trans- plantation as curative therapy of myelodys- plastic syndromes and myeloproliferative disorders. Best Pract Res Clin Haematol. 2006;19(3):519-522.
2. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malig- nancies: replacing high-dose cytotoxic ther- apy with graft-versus-tumor effects. Blood. 2001;97(11):3390-3400.
3. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and post- grafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101(4):1620-1629.
4. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after non- myeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102(6):2021-2030.
5. Sandmaier BM, Maris M, Maloney DG, et al. Low-dose total body irradiation (TBI) conditioning for hematopoietic cell trans- plants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies: a five-year experience. Blood. 2003; 102(11):78-79.
6. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with non- myeloablative conditioning. J Clin Oncol. 2005;23(9):1993-2003.
7. Copelan E, Casper JT, Carter SL, et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant. 2007; 13 (12):1469-1476.
8. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A- matched sibling donors. Transplantation. 1974;18(4):295-304.
9. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new represen- tations of old estimators. Stat Med. 1999;18(6):695-706.
10. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allo-
geneic transplantation for patients with myelodysplastic syndrome or acute myel- ogenous leukemia with multilineage dyspla- sia: a retrospective analysis. Leukemia. 2006;20(1):128-135.
11. Laport GG, Sandmaier BM, Storer BE, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplanta- tion for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008;14(2):246-255.
12. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradi- ation regimens. Blood. 1990; 76(9):1867- 1871.
13. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow trans- plantation. Blood. 1997;89(8): 3048-3054.
14. Hogan WJ, Little MT, Zellmer E, et al. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. Biol Blood Marrow Transplant. 2003;9(8):489-495.
15. Storb R, Raff RF, Appelbaum FR, et al. Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. Blood. 1989;74(3):1139-1143.
16. Storb R, Raff RF, Appelbaum FR, et al. Fractionated versus single-dose total body irradiation at low and high dose rates to con- dition canine littermates for DLA-identical marrow grafts. Blood. 1994;83(11): 3384- 3389.
17. Stelljes M, Bornhauser M, Kroger M, et al. Conditioning with 8-Gy total body irradia- tion and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood. 2005; 106(9):3314-3321.
18. Appelbaum FR, Brown P, Sandmaier B, et al. Antibody-radionuclide conjugates as part of a myeloblative preparative regimen for mar- row transplantation. Blood. 1989; 73(8):2202-2208.
19. Pagel JM, Gooley TA, Rajendran J, et al. Allogeneic hematopoietic cell transplanta- tion after conditioning with 131 I-anti- CD45 antibody plus fludarabine and low- dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syn-
drome. Blood. 2009;114(27):5444-5453.
20. Gopal AK, Guthrie KA, Rajendran J, et al. 90 Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
Blood. 2011;118(4):1132-1139.
21. Sandmaier BM, Bethge WA, Wilbur DS, et
al. Bismuth 213-labeled anti-CD45 radioim- munoconjugate to condition dogs for non- myeloablative allogeneic marrow grafts. Blood. 2002;100(1):318-326.
22. Chen Y, Kornblit B, Hamlin DK, et al. Durable donor engraftment after radioim- munotherapy using alpha-emitter astatine- 211-labeled anti-CD45 antibody for condi- tioning in allogeneic hematopoietic cell transplantation. Blood. 2012;119(5):1130- 1138.
23. Nakamae H, Wilbur DS, Hamlin DK, et al. Biodistribution, myelosuppression, and tox- icities in mice treated with an anti-CD45 antibody labeled with the α-emitting radionuclides bismuth-213 or astatine-211. Cancer Res. 2009;69(6):2408-2415.
24. Kornblit B, Maloney DG, Storer BE, et al. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor trans- plantation. Haematologica. 2014; 99(10): 1624-1631.
25. Sandmaier BM, Maloney DG, Storer BE, et al. Sirolimus combined with mycophenolate mofetil (MMF) and cyclosporine (CSP) sig- nificantly improves prevention of acute graft-versus-host-disease (GVHD) after unrelated hematopoietic cell transplantation (HCT): Results from a phase III randomized multi-center trial. Blood. 2016;128(22):506.
26. Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodys- plastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010; 28(3):405-411.
27. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced- intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28(11):1878-1887.
28. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syn- dromes. J Clin Oncol. 2017;35(11):1154- 1161.
29. Storb R, Sandmaier BM. Nonmyeloablative allogeneic hematopoietic cell transplanta- tion. Haematologica. 2016;101(5):521-530.
haematologica | 2019; 104(6)
1229